PAI
KPTI icon

Palo Alto Investors’s Karyopharm Therapeutics KPTI Stock Holding History

Palo Alto Investors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-187,911
Closed -$810K – 45
2025
Q2 		$810K Sell
187,911
-136,121
-42% -$668K 0.17% 39
2025
Q1 		$1.21M Sell
324,032
-3,101
-0.9% -$26.5K 0.23% 33
2024
Q4 		$3.32M Sell
327,133
-13,013
-4% -$157K 0.51% 22
2024
Q3 		$4.23M Hold
340,146
– – 0.55% 23
2024
Q2 		$4.43M Hold
340,146
– – 0.51% 26
2024
Q1 		$7.7M Hold
340,146
– – 0.87% 23
2023
Q4 		$4.41M Sell
340,146
-38,246
-10% -$515K 0.4% 25
2023
Q3 		$7.61M Hold
378,392
– – 0.72% 17
2023
Q2 		$10.2M Hold
378,392
– – 0.82% 17
2023
Q1 		$22.1M Buy
378,392
+1,347
+0.4% +$66.5K 1.83% 13
2022
Q4 		$19.2M Buy
377,045
+2,276
+0.6% +$158K 1.64% 11
2022
Q3 		$30.7M Hold
374,769
– – 2.43% 11
2022
Q2 		$25.4M Hold
374,769
– – 2.21% 12
2022
Q1 		$41.4M Buy
374,769
+10,072
+3% +$1.26M 3.2% 11
2021
Q4 		$35.2M Buy
364,697
+5,827
+2% +$581K 2.25% 14
2021
Q3 		$31.3M Hold
358,870
– – 1.89% 15
2021
Q2 		$55.6M Buy
358,870
+1,293
+0.4% +$188K 3.06% 14
2021
Q1 		$56.4M Buy
357,577
+6,400
+2% +$1.35M 3.22% 13
2020
Q4 		$81.5M Buy
351,177
+12,100
+4% +$2.8M 4.27% 8
2020
Q3 		$74.3M Buy
339,077
+57,780
+21% +$14.1M 4.08% 10
2020
Q2 		$79.9M Sell
281,297
-5,363
-2% -$1.59M 4.8% 9
2020
Q1 		$82.6M Sell
286,660
-19,673
-6% -$5.43M 6.92% 6
2019
Q4 		$88.1M Sell
306,333
-16,477
-5% -$3.57M 4.85% 10
2019
Q3 		$46.6M Sell
322,810
-28,008
-8% -$3.8M 3.1% 15
2019
Q2 		$31.5M Hold
350,818
– – 1.53% 19
2019
Q1 		$30.7M Buy
350,818
+38,461
+12% +$4.26M 1.28% 19
2018
Q4 		$43.9M Buy
312,357
+1,469
+0.5% +$248K 2.34% 14
2018
Q3 		$79.4M Hold
310,888
– – 3.21% 12
2018
Q2 		$79.2M Buy
310,888
+65,556
+27% +$16.2M 3.17% 12
2018
Q1 		$49.4M Buy
245,332
+9,036
+4% +$1.8M 2.11% 16
2017
Q4 		$34M Buy
236,296
+3,057
+1% +$491K 1.47% 19
2017
Q3 		$38.4M Buy
233,239
+2,067
+0.9% +$296K 1.62% 19
2017
Q2 		$31.4M Buy
231,172
+4,074
+2% +$603K 1.47% 18
2017
Q1 		$43.7M Buy
227,098
+13,738
+6% +$2.21M 2.07% 16
2016
Q4 		$30.1M Buy
213,360
+7,637
+4% +$1.03M 1.72% 19
2016
Q3 		$30M Sell
205,723
-3,573
-2% -$429K 1.74% 19
2016
Q2 		$21.1M Buy
209,296
+2,753
+1% +$358K 1.59% 19
2016
Q1 		$27.6M Sell
206,543
-967
-0.5% -$107K 2.15% 14
2015
Q4 		$41.2M Buy
207,510
+1,794
+0.9% +$388K 2.3% 12
2015
Q3 		$32.5M Buy
205,716
+90,281
+78% +$24.1M 1.56% 12
2015
Q2 		$47.1M Buy
115,435
+52,033
+82% +$22.5M 2.09% 13
2015
Q1 		$29.1M Buy
+63,402
New +$27.3M 1.44% 14

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Palo Alto Investors's KPTI Position: Q3 2025 in Review

Palo Alto Investors sold out of Karyopharm Therapeutics (KPTI) in Q3 2025, closing a stake of 187,911 shares — an estimated $810K sold.

Palo Alto Investors first reported a position in KPTI in Q1 2015 and held it in 42 quarters. The position peaked at $88.1M in Q4 2019. 52 funds tracked by Wall St. Rank hold KPTI as of Q3 2025.

  • Palo Alto Investors reported no remaining Karyopharm Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Palo Alto Investors sold 187,911 Karyopharm Therapeutics shares in Q3 2025, an estimated $810K.
  • Palo Alto Investors first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 42 quarters.
  • Palo Alto Investors's Karyopharm Therapeutics position peaked at $88.1M in Q4 2019.
  • 52 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2025.

Based on Palo Alto Investors's 13F filing for Q3 2025, filed 14 Nov 2025.